L1CAM and neoplasm: When we stratified the expression of high L1CAM with the grading of the disease, we found that higher L1CAM expression predicted a significant shorter DFS in the subgroup of patients with G3 tumor (5y-DFS, 67.7% vs 16.6%, P = 0.004) (Fig. 3d); the expression of L1CAM did not predict risk of recurrence in G1/2 patients (p = 0.47) (Fig. 3c).